早期阶段[18F]PI-2620 tau-PET与[18F]flutemetamol淀粉样蛋白PET记录对灌注缺损的评估比较
本研究在64例疑似神经退行性疾病患者中比较[18F]PI-2620 tau-PET早期灌注加权相位与[18F]flutemetamol淀粉样蛋白PET早期相位作为灌注/代谢缺损替代指标的效能,并以15名无β-淀粉样蛋白和tau病理证据的正常志愿者为对照。两种示踪剂灌注加权图像的z分数在全脑高度相关,尤其在额叶和顶叶(R=0.83±0.08;范围0.61-0.95)。结论认为两种示踪剂早期灌注相位大致等效,均可通过单一PET扫描同时评估淀粉样蛋白/tau状态和神经元活动。
要点
- 64例疑似神经退行性疾病患者中,两种示踪剂灌注加权图像z分数全脑高度相关(R=0.83±0.08)。
- 额叶和顶叶为患者组灌注缺损最显著区域,两种示踪剂在该区域相关性最高。
- 单个患者按区域z分数相关良好(R=0.57±0.15),存在显著灌注缺损时相关更佳(R=0.66±0.15)。
核心结论
- [18F]PI-2620 tau-PET与[18F]flutemetamol淀粉样蛋白PET的早期灌注相位大致等效,可反映多种神经退行性疾病患者区域和脑叶神经元损伤。
- 任一种示踪剂均可通过评估淀粉样蛋白/tau状态和神经元活动提供两条诊断信息通道。
研究设计与样本
- 研究纳入64例疑似神经退行性疾病患者,获取[18F]PI-2620早期相位(注射后0.5-2.5分钟)和[18F]flutemetamol早期相位(注射后0-10分钟)PET记录。
- 以15名无β-淀粉样蛋白和tau病理证据的正常志愿者作为对照队列,比较全局均值归一化图像(SUVr)。
- 计算246个Brainnetome感兴趣区的示踪剂摄取区域组间差异z分数,采用Pearson相关系数评估两种示踪剂z分数的相关性。
- 按脑叶分区、显著神经元损伤区域(z分数<-3)及不同神经退行性疾病实体(如阿尔茨海默病或4R-tau蛋白病)进行亚组分析。
- 采用偏回归分析区域灌注改变与认知测试临床评分的关系。
主要发现
- 两种示踪剂灌注加权图像的z分数在全脑高度相关,尤其在额叶和顶叶——患者组灌注缺损最显著区域(R=0.83±0.08;范围0.61-0.95)。
- 单个患者按区域z分数相关良好(R=0.57±0.15;范围0.16-0.90),存在显著灌注缺损时相关性更佳(R=0.66±0.15;范围0.28-0.90)。
- 两种示踪剂均显示患者组额叶和顶叶灌注缺损显著。
关键数值与推荐
- 全脑区域z分数相关性:R=0.83±0.08(范围0.61-0.95)。
- 单个患者按区域z分数相关性:R=0.57±0.15(范围0.16-0.90)。
- 存在显著灌注缺损时单个患者按区域z分数相关性:R=0.66±0.15(范围0.28-0.90)。
- 显著神经元损伤区域定义为z分数<-3。
- 早期相位采集时间:[18F]PI-2620为注射后0.5-2.5分钟,[18F]flutemetamol为注射后0-10分钟。
临床怎么用
- 作者认为,[18F]PI-2620 tau-PET和[18F]flutemetamol淀粉样蛋白PET的早期灌注相位大致等效,可作为区域和脑叶神经元损伤的灌注缺损指标。
- 作者认为,任一种示踪剂均可通过评估淀粉样蛋白/tau状态和神经元活动提供两条诊断信息通道。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Characteristic features of amyloid-PET (A), tau-PET (T), and FDG-PET (N) can serve for the A/T/N classification of neurodegenerative diseases. Recent studies showed that the early, perfusion-weighted phases of amyloid- or tau-PET recordings serve to detect cerebrometabolic deficits equally to FDG-PET, therefore providing a surrogate of neuronal injury. As such, two channels of diagnostic information can be obtained in the setting of a single PET scan. However, there has hitherto been no comparison of early-phase amyloid- and tau-PET as surrogates for deficits in perfusion/metabolism. Therefore, we undertook to compare [18F]flutemetamol-amyloid-PET and [18F]PI-2620 tau-PET as "one-stop shop" dual purpose tracers for the detection of neurodegenerative disease. METHODS: We obtained early-phase PET recordings with [18F]PI-2620 (0.5-2.5 min p.i.) and [18F]flutemetamol (0-10 min p.i.) in 64 patients with suspected neurodegenerative disease. We contrasted global mean normalized images (SUVr) in the patients with a normal cohort of 15 volunteers without evidence of increased pathology to β-amyloid- and tau-PET examinations. Regional group differences of tracer uptake (z-scores) of 246 Brainnetome volumes of interest were calculated for both tracers, and the correlations of the z-scores were evaluated using Pearson's correlation coefficient. Lobar compartments, regions with significant neuronal injury (z-scores < - 3), and patients with different neurodegenerative disease entities (e.g., Alzheimer's disease or 4R-tauopathies) served for subgroup analysis. Additionally, we used partial regression to correlate regional perfusion alterations with clinical scores in cognition tests. RESULTS: The z-scores of perfusion-weighted images of both tracers showed high correlations across the brain, especially in the frontal and parietal lobes, which were the brain regions with pronounced perfusion deficit in the patient group (R = 0.83 ± 0.08; range, 0.61-0.95). Z-scores of individual patients correlated well by region (R = 0.57 ± 0.15; range, 0.16-0.90), notably when significant perfusion deficits were present (R = 0.66 ± 0.15; range, 0.28-0.90). CONCLUSION: The early perfusion phases of [18F]PI-2620 tau- and [18F]flutemetamol-amyloid-PET are roughly equivalent indices of perfusion defect indicative of regional and lobar neuronal injury in patients with various neurodegenerative diseases. As such, either tracer may serve for two diagnostic channels by assessment of amyloid/tau status and neuronal activity.
引用
- Völter F, Beyer L, Eckenweber F, et al. Assessment of perfusion deficit with early phases of [18F]PI-2620 tau-PET versus [18F]flutemetamol-amyloid-PET recordings. Eur J Nucl Med Mol Imaging. 2022. PMID: 36572740. doi:10.1007/s00259-022-06087-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。